Key Points
- Director J. Scott Garland sold 13,000 Enliven shares at an average price of $46.67, generating $606,710 and reducing his direct stake by 50% to 13,000 shares.
- Enliven shares opened at $45.47, with a $3.33 billion market capitalization and a 52-week range of $14.78 to $62.32. The company recently reported a quarterly loss of $0.49 per share, missing estimates of a $0.39 loss.
- Analysts remain broadly positive, with 10 Buy ratings and one Sell rating producing a “Moderate Buy” consensus and an average price target of $74.44; institutional investors own 95.08% of the stock.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director J. Scott Garland sold 13,000 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $46.67, for a total transaction of $606,710.00. Following the completion of the transaction, the director directly owned 13,000 shares of the company's stock, valued at approximately $606,710. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Enliven Therapeutics Stock Performance
Shares of NASDAQ:ELVN opened at $45.47 on Tuesday. The company has a fifty day moving average of $55.09 and a 200-day moving average of $47.51. The company has a market capitalization of $3.33 billion, a PE ratio of -27.23 and a beta of 0.24. Enliven Therapeutics, Inc. has a 52-week low of $14.78 and a 52-week high of $62.32.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). On average, equities analysts forecast that Enliven Therapeutics, Inc. will post -1.75 EPS for the current fiscal year.
Analyst Ratings Changes
Several research firms have recently weighed in on ELVN. JonesTrading boosted their price target on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a "buy" rating in a report on Monday, June 29th. Mizuho raised their price objective on shares of Enliven Therapeutics from $62.00 to $73.00 and gave the company an "outperform" rating in a report on Tuesday, August 18th. William Blair started coverage on shares of Enliven Therapeutics in a research report on Tuesday, August 18th. They set an "outperform" rating on the stock. Barclays initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, August 18th. They set an "overweight" rating and a $78.00 target price on the stock. Finally, HC Wainwright upped their price target on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a "buy" rating in a research report on Thursday, July 9th. Ten equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Enliven Therapeutics has an average rating of "Moderate Buy" and an average price target of $74.44.
Read Our Latest Report on Enliven Therapeutics
Institutional Trading of Enliven Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. KBC Group NV bought a new position in shares of Enliven Therapeutics in the 1st quarter worth about $38,000. State of Wyoming bought a new stake in shares of Enliven Therapeutics during the 2nd quarter valued at about $96,000. FNY Investment Advisers LLC bought a new stake in shares of Enliven Therapeutics during the 2nd quarter valued at about $126,000. Arizona State Retirement System grew its stake in Enliven Therapeutics by 45.1% during the second quarter. Arizona State Retirement System now owns 13,007 shares of the company's stock worth $660,000 after purchasing an additional 4,042 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in Enliven Therapeutics by 21.2% during the first quarter. The Manufacturers Life Insurance Company now owns 23,441 shares of the company's stock worth $919,000 after purchasing an additional 4,105 shares during the period. Institutional investors and hedge funds own 95.08% of the company's stock.
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics, Inc (NASDAQ: ELVN) is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule medicines for the treatment of cancer. The company seeks to develop therapies designed to address significant unmet needs in oncology, with an emphasis on targeted treatments that may offer improved efficacy, safety, or durability.
Enliven's pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for patients with chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for the treatment of HER2-driven cancers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
